Skip to main content

CCTG Connection



Published:
Category: Group updates
departing patient representatives Marie-Térèse Little and Carol Gordon

The CCTG Patient Representative Committee (PRC) sends a heartfelt thank you to two key members who will be leaving us this month, Marie-Térèse Little and Carol Gordon. Their contributions have been transformative, and we are fortunate to have had their unwavering engagement and insight over the years. Their dedication will continue to inspire and elevate the work of the committee to improve cancer research for patients everywhere.

Read More

Published:
Category: Group updates
The CCTG Annual Spring Meeting

The CCTG Annual Spring Meeting is only 5 weeks away! If you have not registered or requested an Invitation, please do so now! Here are some things for you to keep in mind:

Meeting Information

All meeting information is available on the Spring Meeting Web Page and includes:

Read More

Published:
Category: News
CAN-PACT - Building a Research, Practice and Policy Foundation

A new national initiative as been funded by the Canadian Cancer Society, through their Breakthrough Team Grant competition. The Canadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT), is bringing together researchers, clinicians, policymakers, and people living with advanced cancer to explore the potential of psychedelic-assisted therapy as a transformative approach to cancer care.

Read More

Published:
Category: Publications
Publication: PA6, CE6, CLC2, CRC6, CO17
A series of publication in relation to CCTG trials comprising secondary analysis, updated analysis and nested cohort. Read More

Published:
Category: Publications
Publication: LYC1, REC4, CE8
Primary publications for LYC1: Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL, and REC4: Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy and CE8: Marizomib for patients with newly diagnosed glioblastoma. Read More

Published:
Category: Trials
Trial closure: PA7
PA7: A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma trial has permanently closed. 

Primary Publication

Read More



Published:
Category: Group updates
Session 4: Introduction to RIPPLE: CCTG's rostering and participants list system

CCTG will be holding the next CRA Lunch and Learn on Wednesday March 26th, 2025, at 12 pm ET. Session 4 will cover the topic of Introduction to RIPPLE:  CCTG's rostering and participants list system 

 

Read More

Published:
Category: Group updates
CCTG is looking for a new Gastro-Intestinal patient representative

The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Gastro-Intestinal Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Gastro-Intestinal Disease Site Committee, the Gastro-Intestinal Disease Site Executive Committee, and the CCTG Patient Representative Committee.

Read More